AIRSUPRA Market Size, Forecast, and Market Insight - 2032

AIRSUPRA Market Size, Forecast, and Market Insight − 2032

“AIRSUPRA Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about AIRSUPRA for Asthma in the seven major markets. A detailed picture of the AIRSUPRA for Asthma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the AIRSUPRA for Asthma. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AIRSUPRA market forecast analysis for Asthma in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Asthma.

Drug Summary

FDA has approved AIRSUPRA (albuterol and budesonide) inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma 18 years and older. AIRSUPRA contains both albuterol and budesonide. These drugs represent two classes of medications (a short-acting selective beta2-adrenergic agonist and a synthetic corticosteroid) that have different effects on clinical, physiological, and inflammatory indices of asthma.

The treatment works to relax the muscles and reduce inflammation in the lung airways to reduce the risk of severe asthma attacks. AIRSUPRA is given as two oral inhalations of a combination of albuterol 90 mcg and budesonide 80 mcg per inhalation (total dose albuterol 180 mcg and budesonide 160 mcg) as needed for asthma symptoms.

The FDA approved it in January 2023.

Dosage and administration

The recommended dosage of AIRSUPRA is albuterol 180 mcg and budesonide 160 mcg (administered as two actuation of AIRSUPRA [albuterol/budesonide 90 mcg/80 mcg]) as needed for asthma symptoms by oral inhalation. Do not take more than six doses (12 inhalations) in 24 h.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the AIRSUPRA description, mechanism of action, dosage and administration, research and development activities in Asthma.

Elaborated details on AIRSUPRA regulatory milestones and other development activities have been provided in this report.

The report also highlights the AIRSUPRA research and development activities in Asthma across the United States, Europe, and Japan.

The report also covers the patents information with expiry timeline around AIRSUPRA.

The report contains forecasted sales of AIRSUPRA for Asthma till 2032.

Comprehensive coverage of the late-stage emerging therapies for Asthma.

The report also features the SWOT analysis with analyst views for AIRSUPRA in Asthma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AIRSUPRA Analytical Perspective by DelveInsight

In-depth AIRSUPRA Market Assessment

This report provides a detailed market assessment of AIRSUPRA for Asthma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

AIRSUPRA Clinical Assessment

The report provides the clinical trials information of AIRSUPRA for Asthma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Asthma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AIRSUPRA dominance.

Other emerging products for Asthma are expected to give tough market competition to AIRSUPRA and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AIRSUPRA in Asthma.

Our in-depth analysis of the forecasted sales data of AIRSUPRA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AIRSUPRA in Asthma.

Key Questions

What is the product type, route of administration and mechanism of action of AIRSUPRA?

What is the clinical trial status of the study related to AIRSUPRA in Asthma and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AIRSUPRA development?

What are the key designations that have been granted to AIRSUPRA for Asthma?

What is the forecasted market scenario of AIRSUPRA for Asthma?

What are the forecasted sales of AIRSUPRA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?

What are the other emerging products available and how are these giving competition to AIRSUPRA for Asthma?

Which are the late-stage emerging therapies under development for the treatment of Asthma?